Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Global RNA-sequencing of a pediatric AML primary sample treated with Tamibarotene or vehicle

ABSTRACT: Global RNA-sequencing of a pediatric AML primary sample treated with Tamibarotene or vehicle

PROVIDER: PRJNA650298 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12369750_1.fastq.gz	Fastqsanger.gz
	SRR12369750_2.fastq.gz	Fastqsanger.gz
	SRR12369751_1.fastq.gz	Fastqsanger.gz
	SRR12369751_2.fastq.gz	Fastqsanger.gz
	SRR12369752_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

Global RNA-sequencing of a pediatric AML primary sample treated with Tamibarotene or vehicle

Project description:The purpose of this study was to assess the global transcriptional changes in a pediatric AML primary sample treated with Tamibarotene. This patient sample has a retinoic acid receptor alpha (RARA) super-enhancer, which is correlated with higher RARA mRNA levels and increased sensitivity to Tamibarotene in vitro and in vivo (Patient-derived xenograft mouse model).

2021-08-01 | GSE155559 | GEO

Global RNA-sequencing of a pediatric AML primary sample treated with Tamibarotene or vehicle

Project description:Global RNA-sequencing of a pediatric AML primary sample treated with Tamibarotene or vehicle

| PRJNA650298 | ENA

Global Proteomic Profiling of Pediatric AML: A Pilot Study

Project description:Acute Myeloid Leukemia (AML) is a heterogeneous disease with several recurrent cytogenetic abnormalities. Despite genomics and transcriptomics profiling efforts to understand AML’s heterogeneity, studies focused on the proteomic profiles associated with pediatric AML cytogenetic features remain limited. Furthermore, the majority of biological functions within cells are operated by proteins (i.e., enzymes) and most drugs target the proteome rather than the genome or transcriptome, thus, highlighting the significance of studying proteomics.

2023-09-26 | PXD043982 | Pride

Genomic analysis of pediatric AML by whole transcriptome sequencing [pediatric AML patients]

Project description:Pediatric AML is an aggressive hematological malignancy associated with distinctive genomic features. We employed RNA-seq to study fusion genes and clinically relevant gene expression patterns in pediatric AML patients.

2023-05-02 | GSE222814 | GEO

Genomic analysis of pediatric AML by whole transcriptome sequencing [pediatric AML patients]

Project description:Genomic analysis of pediatric AML by whole transcriptome sequencing [pediatric AML patients]

| PRJNA923607 | ENA

ChIPseq for pediatric AML patients

Project description:ChIPseq for pediatric AML patients

| PRJNA779619 | ENA

Gene expression profile of pediatric AML

Project description:Gene expression data were obtained from 130 pediatric AML patients who were enrolled on the AML99 study conducted by the Japanese Childhood AML Cooperative Study Group. RNA samples obtained at the time of diagnosis were analyzed using GeneChip Human Genome U133 plus 2.0 array (Affymetrix).

2013-04-01 | E-GEOD-35784 | biostudies-arrayexpress

Expression data from pediatric AML patients

Project description:Pediatric acute myeloid leukemia (AML) is a heterogeneous disease characterized by non-random genetic aberrations related to outcome. Detecting these aberrations however still lead to failures or false negative results. Therefore, we focused on the potential of gene expression profiles (GEP) to classify pediatric AML. Gene expression microarray data of 237 children with AML were generated and cases were split into a discovery cohort (n=157) and an independent validation cohort (n=80). Next, a double-loop cross validation approach was used to generate a subtype-predictive GEP in the discovery cohort which was then tested for its true predictive value in the independent validation cohort. 237 bone marrow and peripheral blood samples were collected at diagnosis and frozen. They were later thawed and hybridized to Affymetrix U133 Plus 2.0 arrays.

2010-10-21 | E-GEOD-17855 | biostudies-arrayexpress

Gene expression profile of pediatric AML

Project description:Gene expression data were obtained from 130 pediatric AML patients who were enrolled on the AML99 study conducted by the Japanese Childhood AML Cooperative Study Group.

2013-04-01 | GSE35784 | GEO

microRNA profiling in pediatric AML

Project description:MicroRNAs (miRNAs) play a pivotal role in the regulation of hematopoiesis and development of leukemia. Great interest emerged in modulating miRNA expression for therapeutic purposes. In order to identify miRNAs, which specifically suppress leukemic growth of AML with t(8;21), inv(16) or MLL-rearrangement by inducing differentiation, we conducted a miRNA expression profiling in a cohort of 90 cytogenetically characterized, de novo pediatric AML cases. Four miRNAs, specifically downregulated in MLL-rearranged, t(8;21) or inv(16) AMLs, were characterized by their tumor suppressive properties in cell lines representing those respective cytogenetic groups. Among those, forced expression of miR-9 reduced leukemic growth and induced monocytic differentiation of t(8;21) AML cell lines in vitro and in vivo. The tumor suppressive functions of miR-9 were specifically restricted to AML cell lines and primary leukemic blasts with t(8;21). On the other hand, these functions were not evident in AML blasts from patients with MLL-rearrangements. We showed that miR-9 exerts its effects through the cooperation with let-7 to repress the oncogenic LIN28B/HMGA2 axis. Thus, miR-9 is a tumor suppressor-miR which acts in a stringent cell context-dependent manner. In order to identify miRNAs, which specifically suppress leukemic growth of AML with t(8;21) (n=21), inv(16) (n=17) or MLL-rearrangement (n=35) by inducing differentiation, we conducted a miRNA expression profiling in a cohort of 90 cytogenetically characterized, de novo pediatric AML cases, which also included 12 t(15;17) and 5 t(7;12) samples.

2014-01-01 | E-GEOD-52541 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data